Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

Bing Z Carter, PhD, Po Yee Mak, Vivian Ruvolo, MS, Wenjing Tao, Paul Hughes, Xiaoyue Chen, PK Morrow, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-141399

Published: 2020

Journal Articles

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

Kotoko Yamatani, MD, Tomohiko Ai, MDPhD, Kaori Saito, Haeun Yang, Vivian Ruvolo, MS, Po Yee Mak, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Hironori Harada, MD PhD, Kazuhiro Katayama, PhD, Takashi Miida, MD PhD, Marina Konopleva, MD PhD, Weiguo Zhang, MD PhD, Bing Z Carter, PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136587

Published: 2020

Journal Articles

High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML

Muharrem Muftuoglu, MD, Po Yee Mak, Vivian Ruvolo, MS, Yuki Nishida, MDPhD, Peter P. Ruvolo, PhD, Bing Z Carter, PhD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-143371

Published: 2020

Journal Articles

Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias

Yuki Nishida, MDPhD, Jo Ishizawa, MDPhD, Edward Ayoub, PhD MS, BSc, Rafael Heinz Montoya, BS, Vivian Ruvolo, MS, Kensuke Kojima, MD PhD, Naval Daver, MD, Arnaud Lesegretain, Sharon Shacham, PhD MBA, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-140768

Published: 2020

Journal Articles

Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML

Bing Z Carter, PhD, Po Yee Mak, Wenjing Tao, Vivian Ruvolo, MS, Xuan Zhang, PhD, Yuki Nishida, MD PhD, Steven M. Kornblau, MD, Paul Hughes, Xiaoyue Chen, PK Morrow, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-141417

Published: 2020

Journal Articles

The Novel Dihydroorotate Dehydrogenase (DHODH) Inhibitor PTC299 Inhibit De Novo Pyrimidine Synthesis with Broad Anti-Leukemic Activity Against Acute Myeloid Leukemia

Sujan Piya, PhD, Marla Weetall, PhD, Josephine Sheedy, BS, MSc, Balmiki Ray, PhD, Huaxian Ma, MS, Kensuke Kojima, MD PhD, Vivian Ruvolo, MS, Mahesh Basyal, BS, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-139940

Published: 2020

Journal Articles

The Direct Interactions with Bone Marrow Microenvironment Confer Resistance to the Inhibition of Oxidative Phosphorylation in AML

Yoko Tabe, MD PhD, Kaori Saito, Kotoko Yamatani, MD, Haeun Yang, Rodrigo Jacamo, PhD, Helen Ma, MS, Vivian Ruvolo, MS, Qi Zhang, PhD, Vinitha Mary Kuruvilla, MSc, Natalia Baran, PhDMD, Junichi Imoto, Kazuho Ikeo, PhD, Koya Suzuki, PhD, Takashi Miida, MD PhD, Michael Andreeff, MD PhD, Christopher P Vellano, Joseph R Marszalek, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-137366

Published: 2020

Journal Articles

Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3 -ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-142687

Published: 2020

Journal Articles

Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor

Natalia Baran, PhDMD, Alessia Lodi, PhD, Yogesh Dhungana, PhD, Shannon RENEE Sweeney, PhD, Pandey Renu, PhD, Shelley Herbrich, PhD, Fieke W Hoff, BSc, Anna Skwarska, PhD, Mecit Kaplan, MS, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, MSc, Marc Warmoes, PhD, Shanti Rojas-Sutterlin, PhD, Andre Haman, PhD, Diogo Troggian Veiga, PhD, Ken Furudate, DDM, PhD, Helen Ma, MS, Karine Harutyunyan, PhD, Wentao Yang, Mihai Gagea, MDPhD, Di Du, PhD, May Daher, Luciana Melo Garcia, MD, Sujan Piya, PhD, Vivian Ruvolo, MS, Sriram Shanmugavelandy, Ningping Feng, PhD, Jason P Gay, MS, Ondrej Havranek, MDPhD, Jared Henderson, MS, Katarzyna Tomczak, PhD, Marcin Kaminski, PhD, Daniel Herranz, PharmD, Adolfo Ferrando, MD, PhD, Elias Jabbour, MD, Maria E Di Francesco, PhD, David T. Teachey, MD, Terzah M. Horton, MD PhD, Katayoun Rezvani, MD PhD, Jun J. Yang, PhD, Steven M. Kornblau, MD, Eric Davis, MD, Koichi Takahashi, MD PhD, Michael Andreeff, MD PhD, Joseph R Marszalek, PhD, Philip Lorenzi, PhD, Jiyang Yu, PhD, Stefano Tiziani, PhD, Trang Hoang, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-136801

Published: 2020

Journal Articles

TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1

Bing Z Carter, PhD, Po Yee Mak, Steven M. Kornblau, MD, Wenjing Tao, Yuki Nishida, MD PhD, Vivian Ruvolo, MS, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1271.

https://doi.org/10.1182/blood-2019-124826

Published: 2019

Journal Articles

Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML

Blood (2019) 134 (Supplement_1): 911.

https://doi.org/10.1182/blood-2019-125007

Published: 2019

Journal Articles

Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML

Bing Z Carter, PhD, Po Yee Mak, Marc Warmoes, Wenjing Tao, Philip Lorenzi, Vivian Ruvolo, MS, Lin Tan, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3727.

https://doi.org/10.1182/blood-2019-124453

Published: 2019

Journal Articles

TP73 As Novel Determinant of Resistance to BCL-2 Inhibition in Acute Myeloid Leukemia

Yuki Nishida, MD PhD, Jo Ishizawa, MD PhD, Vivian Ruvolo, MS, Feng Wang, PhD, Koichi Takahashi, MD, Po Yee Mak, Bing Z Carter, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1251.

https://doi.org/10.1182/blood-2019-127182

Published: 2019

Journal Articles

Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells

Bing Z Carter, PhD, Wenjing Tao, Po Yee Mak, Qi Zhang, PhD, Xiangmeng Wang, Vinitha Mary Kuruvilla, MSc, Carli Stewart, Vivian Ruvolo, MS, Venkata Lokesh Battula, PhD, Marina Y Konopleva, MD PhD, Sean Caenepeel, Jude Canon, PhD, Paul Hughes, PK Morrow, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1267.

https://doi.org/10.1182/blood-2019-125725

Published: 2019

Journal Articles

Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc

Yuki Nishida, MD PhD, Jo Ishizawa, MD PhD, Vivian Ruvolo, MS, Kensuke Kojima, MD PhD, Rafael Heinz Montoya, Naval G. Daver, MD, Arnaud Lesegretain, Sharon Shacham, PhD MBA, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 2556.

https://doi.org/10.1182/blood-2019-126950

Published: 2019

Journal Articles

TP73 Isoforms (TAp73 and ΔNp73) Are Overexpressed in Acute Myeloid Leukemias and Potential Therapeutic Targets to Enhance Anti-Leukemia Activities of Bcl-2 and MDM2 Inhibitors

Yuki Nishida, MD PhD, Jo Ishizawa, MD PhD, Vivian Ruvolo, MS, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 2629.

https://doi.org/10.1182/blood-2018-99-113900

Published: 2018

Journal Articles

Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL

Sujan Piya, PhD, Seemana Bhattacharya, PhD, Hong Mu, MD PhD, Vivian Ruvolo, MS, Natalia Baran, PhDMD, Teresa McQueen, MS, R. Eric Davis, MD, Yimin Qian, PhD, Kanak Raina, PhD, M. James You, MD PhD, Marina Y. Konopleva, MD PhD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2018) 132 (Supplement 1): 890.

https://doi.org/10.1182/blood-2018-99-115692

Published: 2018

Journal Articles

Mitochondrial Transfer Confers Microenvironment-Mediated Resistance to Oxphos Inhibition in AML

Haeun Yang, Yoko Tabe, MD PhD, Kaori Saito, Rodrigo Jacamo, PhD, Helen Ma, MS, Vivian Ruvolo, MS, Junichi Imoto, Kazuho Ikeo, PhD, Kaoru Mogushi, PhD, Masaki Hosoya, PhD, Shigeo Yamaguchi, Kotoko Yamatani, MD, Yuko Murakami-Tonami, MD, Koya Suzuki, PhD, Takashi Miida, MD PhD, Michael Andreeff, MD PhD, Joseph R Marszalek, PhD, Marina Y. Konopleva, MD PhD

Blood (2018) 132 (Supplement 1): 430.

https://doi.org/10.1182/blood-2018-99-112933

Published: 2018

Journal Articles

TAM Inhibitor ONO-7475 Combination with Sorafenib Is Effective Using in Vitro and In Vivo Models of FLT3 ITD Acute Myeloid Leukemia

Peter P. Ruvolo, PhD, Huaxian Ma, MS, Vivian Ruvolo, MS, Xiaorui Zhang, BS, Hong Mu, MD PhD, Tomoko Yasuhiro, Kohei Tanaka, Toshio Yoshizawa, PhD, Weiguo Zhang, MD PhD, Jorge E. Cortes, MD, Michael Andreeff, MD PhD, Sean M Post, PhD

Blood (2018) 132 (Supplement 1): 2642.

https://doi.org/10.1182/blood-2018-99-112211

Published: 2018

Journal Articles

Concomitant Targeting of FLT3 and BTK with CG'806 Overcomes FLT3-Inhibitor Resistance through Inhibition of Autophagy

Weiguo Zhang, MD PhD, Guopan Yu, MD, PhD, Hongying Zhang, MD, PhD, Charlie Ly, BS, Bin Yuan, Vivian Ruvolo, MS, Sujan Piya, PhD, Seemana Bhattacharya, PhD, Qi Zhang, PhD, Gautam Borthakur, MD, Venkata Lokesh Battula, PhD, Marina Y. Konopleva, MD PhD, William G Rice, PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 2635.

https://doi.org/10.1182/blood-2018-99-116643

Published: 2018

NARROW

Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML

Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias

Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML

The Novel Dihydroorotate Dehydrogenase (DHODH) Inhibitor PTC299 Inhibit De Novo Pyrimidine Synthesis with Broad Anti-Leukemic Activity Against Acute Myeloid Leukemia

The Direct Interactions with Bone Marrow Microenvironment Confer Resistance to the Inhibition of Oxidative Phosphorylation in AML

Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3 -ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial

Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor

TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1

Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML

Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML

TP73 As Novel Determinant of Resistance to BCL-2 Inhibition in Acute Myeloid Leukemia

Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells

Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc

TP73 Isoforms (TAp73 and ΔNp73) Are Overexpressed in Acute Myeloid Leukemias and Potential Therapeutic Targets to Enhance Anti-Leukemia Activities of Bcl-2 and MDM2 Inhibitors

Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL

Mitochondrial Transfer Confers Microenvironment-Mediated Resistance to Oxphos Inhibition in AML

TAM Inhibitor ONO-7475 Combination with Sorafenib Is Effective Using in Vitro and In Vivo Models of FLT3 ITD Acute Myeloid Leukemia

Concomitant Targeting of FLT3 and BTK with CG'806 Overcomes FLT3-Inhibitor Resistance through Inhibition of Autophagy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only